{"version":"1.0","provider_name":"Merck.com","provider_url":"https:\/\/vip2-msd.com\/merckcom-migrated","author_name":"Merck.com","author_url":"https:\/\/vip2-msd.com\/merckcom-migrated","title":"Merck to Acquire Imago BioSciences, Inc. - Merck.com","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"K0KsqTtMoy\"><a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-imago-biosciences-inc\/\">Merck to Acquire Imago BioSciences, Inc.<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-imago-biosciences-inc\/embed\/#?secret=K0KsqTtMoy\" width=\"600\" height=\"338\" title=\"&#8220;Merck to Acquire Imago BioSciences, Inc.&#8221; &#8212; Merck.com\" data-secret=\"K0KsqTtMoy\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Acquisition expands Merck\u2019s growing hematology portfolio Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (\u201cImago\u201d) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20221121005295\/en\/ \u201cWe continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve,\u201d said Robert M. Davis, president and chief executive officer, Merck. \u201cThis acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology.\u201d Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20221121005295r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"}